Clinical Trials Browser

OTHER_GOV × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all

Cardiovascular Diseases, Erectile Dysfunction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03746054 2025-03-17

PALERMO

Phase 3 Terminated

80 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02381379 2020-09-14

MSIT

Phase 3 Unknown

118 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02161978 2019-11-06

DYVA-AAGG

Completed

93 enrolled

MyeloidOther hematologic neoplasm

Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03062436 2019-07-23

To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission

Phase NA Unknown

27 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00750659 2016-04-20

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Phase 2 Completed

24 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00297570 2007-10-10

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Phase 3 Unknown

90 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical Trials

ED2024

PALERMO

MSIT

DYVA-AAGG

To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy